SAbDab: The Structural Antibody Database

> Structural Summary

Therapeutic	Fresolimumab
Target	TGFB
Heavy Chain	QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS
Light Chain	ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	3eo0 [Fvs: BA, DC], 3eo1 [Fvs: BA, ED, HG, KJ], 4kv5 [Fvs: EE, GG, HH, JJ], 4kxz [Fvs: HL, JI, NM, QP]
95-98% seqID Fv Structure	None

> SAbDab Links

99% seqID Structure	3eo0 [Fvs: BA, DC]
99% seqID Structure	4kxz [Fvs: HL, JI, NM, QP]
99% seqID Structure	4kv5 [Fvs: EE, GG, HH, JJ]
99% seqID Structure	3eo1 [Fvs: BA, ED, HG, KJ]
There are no identical PDB matches to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Fresolimumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

> 3eo0: B/A

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	101	102	103	104	105	106	107	108	109	110	111	112	113
fresolimumab	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S
3eo0	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	30A	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
fresolimumab	E	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K
3eo0	-	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K

> 4kxz: H/L

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	101	102	103	104	105	106	107	108	109	110	111	112	113
fresolimumab	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S
4kxz	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	30A	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
fresolimumab	E	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K
4kxz	-	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K

> 4kv5: E/E

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	101	102	103	104	105	106	107	108	109	110	111	112	113
fresolimumab	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S
4kv5	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	30A	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
fresolimumab	E	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K
4kv5	-	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K

> 3eo1: B/A

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	101	102	103	104	105	106	107	108	109	110	111	112	113
fresolimumab	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S
3eo1	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	Y	T	F	S	S	N	V	I	S	W	V	R	Q	A	P	G	Q	G	L	E	W	M	G	G	V	I	P	I	V	D	I	A	N	Y	A	Q	R	F	K	G	R	V	T	I	T	A	D	E	S	T	S	T	T	Y	M	E	L	S	S	L	R	S	E	D	T	A	V	Y	Y	C	A	S	T	L	G	L	V	L	D	A	M	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	30A	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
fresolimumab	E	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K
3eo1	-	T	V	L	T	Q	S	P	G	T	L	S	L	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	L	G	S	S	Y	L	A	W	Y	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	S	R	A	P	G	I	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	R	L	E	P	E	D	F	A	V	Y	Y	C	Q	Q	Y	A	D	S	P	I	T	F	G	Q	G	T	R	L	E	I	K

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

> Metadata

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (Feb '25)	Phase-I
Estimated Status (Feb '25)	Discontinued
Recorded Developmental Technology	CAT Phage Display
INN Year Proposed	2009
INN Year Recommended	2010
Companies Involved	Cambridge Antibody Technology, Baylor College of Medicine, Genzyme Corporation, Sanofi Genzyme
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Fibrosis, Malignant melanoma, Pulmonary fibrosis, Renal cancer, Focal segmental glomerulosclerosis, Osteogenesis imperfecta
Notes

Thera-SAbDab

FRESOLIMUMAB